Novartis has claimed accelerated approval from the FDA for a second indication for Fabhalta – IgA nephropathy (IgAN) – as it charts a course to blockbuster sales for the drug. The US regulator ...
Shortly after claiming FDA approval for its Filspari therapy for rare kidney disease IgA Nephropathy (IgAN), Travere Therapeutics has said it will price the drug at a discount to a recently ...
The IgAN group needs to be congratulated for coordinating a worldwide effort to develop a universally accepted IgAN classification system. By developing agreed definitions for each pathological ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback